Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Rating of “Reduce” by Brokerages

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been given a consensus rating of “Reduce” by the eight ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.00.

Several analysts have recently weighed in on AMPH shares. Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Thursday, May 14th. Bank of America reiterated an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AMPH. FNY Investment Advisers LLC purchased a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $26,000. Quarry LP acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $32,000. Farther Finance Advisors LLC raised its position in Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Amphastar Pharmaceuticals by 24.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after purchasing an additional 435 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $19.86 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85. Amphastar Pharmaceuticals has a fifty-two week low of $16.65 and a fifty-two week high of $31.26. The firm has a market capitalization of $875.63 million, a PE ratio of 11.96, a price-to-earnings-growth ratio of 3.82 and a beta of 0.89. The stock’s 50-day simple moving average is $19.16 and its 200-day simple moving average is $22.19.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). The business had revenue of $171.17 million for the quarter, compared to analysts’ expectations of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. As a group, equities research analysts forecast that Amphastar Pharmaceuticals will post 2.41 EPS for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.